A routine method for cloning, expressing and purifying Aβ(1-42) for structural NMR studies

Area of Science:

• Biophysics
• Structural Biology
• Neuroscience

Background:

• Nuclear magnetic resonance (NMR) spectroscopy is crucial for atomic-level analysis of biomolecule structure and dynamics.
• Alzheimer's disease research benefits from NMR studies of amyloid-beta peptide (Aβ), but high costs of isotopically enriched Aβ hinder progress.
• Existing biosynthetic methods are challenging for Aβ, and aggregation issues increase costs of solid-phase synthesis.

Purpose of the Study:

• To develop a cost-effective biosynthetic and purification strategy for producing uniformly enriched ¹⁵N and ¹³C¹⁵N Aβ(1-42).
• To overcome the limitations of current methods for obtaining isotopically labeled Aβ for NMR studies.
• To facilitate further investigations into Alzheimer's disease pathogenesis and other misfolding diseases.

Main Methods:

• Developed novel biosynthetic procedures for producing isotopically enriched Aβ(1-42).
• Optimized purification techniques to yield high-purity Aβ(1-42) with reduced aggregation.
• Characterized the purified peptide using solution-state NMR, thioflavin T assays, circular dichroism, electrospray mass spectrometry, and dynamic light scattering.

Main Results:

• Achieved production yields exceeding 10 mg/L of culture media for pure, uniformly enriched ¹⁵N and ¹³C¹⁵N Aβ(1-42).
• Demonstrated long-term stability of the HPLC-purified Aβ(1-42) product.
• Confirmed peptide integrity and stability through multiple biophysical characterization techniques.

Conclusions:

• The developed biosynthetic and purification methods significantly reduce the cost and increase the accessibility of isotopically enriched Aβ(1-42).
• This advancement provides a stable, high-yield source of labeled Aβ, enabling more extensive NMR investigations.
• The findings are expected to accelerate research into Alzheimer's disease and potentially other protein misfolding disorders.